Literature DB >> 10404859

Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.

T Murakami1, S Mizuno, K Ohsato, I Moriuchi, Y Arai, Y Nio, B Kaku, Y Takahashi, M Ohnaka.   

Abstract

This study investigates the effects of troglitazone, an insulin sensitizer, on the clinical manifestation of coronary vasospastic angina pectoris in patients with diabetes mellitus. Troglitazone reduces frequency of angina pectoris and improves endothelial function.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10404859     DOI： 10.1016/s0002-9149(99)00199-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  14 in total

1.  The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank.

Authors:  G D Tan; M J Neville; E Liverani; S M Humphreys; J M Currie; L Dennis; B A Fielding; F Karpe
Journal:  Diabetologia       Date:  2005-12-17       Impact factor: 10.122

Review 2.  Soluble guanylate cyclase: a potential therapeutic target for heart failure.

Authors:  Mihai Gheorghiade; Catherine N Marti; Hani N Sabbah; Lothar Roessig; Stephen J Greene; Michael Böhm; John C Burnett; Umberto Campia; John G F Cleland; Sean P Collins; Gregg C Fonarow; Phillip D Levy; Marco Metra; Bertram Pitt; Piotr Ponikowski; Naoki Sato; Adriaan A Voors; Johannes-Peter Stasch; Javed Butler
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

Review 3.  Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.

Authors:  S Giannini; M Serio; A Galli
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 4.  Peroxisome proliferator-activated receptor gamma and atherosclerosis.

Authors:  Nikolaus Marx
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

5.  Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production.

Authors:  Jennifer M Kleinhenz; Dean J Kleinhenz; Shaojin You; Jeffrey D Ritzenthaler; Jason M Hansen; David R Archer; Roy L Sutliff; C Michael Hart
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-07       Impact factor: 4.733

Review 6.  The impact of antidiabetic therapies on cardiovascular disease.

Authors:  Brandy Panunti; Biju Kunhiraman; Vivian Fonseca
Journal:  Curr Atheroscler Rep       Date:  2005-02       Impact factor: 5.113

7.  PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.

Authors:  Nikolaus Marx; Bettina Kehrle; Klaus Kohlhammer; Miriam Grüb; Wolfgang Koenig; Vinzenz Hombach; Peter Libby; Jorge Plutzky
Journal:  Circ Res       Date:  2002-04-05       Impact factor: 17.367

8.  Multifocal severe coronary artery vasospasm mistaken for diffuse atherosclerosis: a case report.

Authors:  Sarfraz Ahmed Nazir; Sheraz Nazir; Sanjay Kumar; Charles Ilsley
Journal:  Case Rep Med       Date:  2010-09-01

Review 9.  Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.

Authors:  P Spallarossa; A Barsotti; R Cordera; G Ghigliotti; D Maggi; C Brunelli
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

Review 10.  The Role of PPARgamma in pulmonary vascular disease.

Authors:  C Michael Hart
Journal:  J Investig Med       Date:  2008-02       Impact factor: 2.895
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.